Movement Alert｜DotBio-B Falls 5.04% in Regular Trading, ASCO Rebound Fades as Southbound Fund Selling Persists

Market Focus06-09

On June 9, DotBio-B declined 5.04% in regular trading, trading at HK$171.6/share, with trading volume of HK$37.87 million. The stock continues its downward trend after a brief ASCO-driven rebound on June 5 proved short-lived.

The company staged a 6% bounce on June 5 supported by consecutive share buybacks and positive ASCO clinical data catalysts, including Phase I data for its B7-H4 ADC DB-1312/BG-C9074 partnered with BeiGene. However, the rebound failed to hold, with the stock falling 5.25% on June 8 as selling pressure overwhelmed buyback efforts. Despite repurchasing a cumulative 262,400 shares since late May totaling approximately HK$53.3 million year-to-date, the company has been unable to stem persistent outflows. Southbound funds have reduced holdings by approximately 2.86 million shares over the past 20 trading days, bringing their stake down to around 29.66% of issued shares.

The broader Biotechnology sector is under significant pressure today, with Innovent Bio down 4.37%, Akeso down 3.79%, Remegen down 3.49%, BeiGene down 2.33%, and SKB Bio down 1.57%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143006270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143006270","market":"hk","top_or_hot":-1,"title":"Movement Alert｜DotBio-B Falls 5.04% in Regular Trading, ASCO Rebound Fades as Southbound Fund Selling Persists","media":"Market Focus","content":"<p><p>On June 9, DotBio-B declined 5.04% in regular trading, trading at HK$171.6/share, with trading volume of HK$37.87 million. The stock continues its downward trend after a brief ASCO-driven rebound on June 5 proved short-lived.</p><p>The company staged a 6% bounce on June 5 supported by consecutive share buybacks and positive ASCO clinical data catalysts, including Phase I data for its B7-H4 ADC DB-1312/BG-C9074 partnered with BeiGene. However, the rebound failed to hold, with the stock falling 5.25% on June 8 as selling pressure overwhelmed buyback efforts. Despite repurchasing a cumulative 262,400 shares since late May totaling approximately HK$53.3 million year-to-date, the company has been unable to stem persistent outflows. Southbound funds have reduced holdings by approximately 2.86 million shares over the past 20 trading days, bringing their stake down to around 29.66% of issued shares.</p><p>The broader Biotechnology sector is under significant pressure today, with Innovent Bio down 4.37%, Akeso down 3.79%, Remegen down 3.49%, BeiGene down 2.33%, and SKB Bio down 1.57%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DotBio-B Falls 5.04% in Regular Trading, ASCO Rebound Fades as Southbound Fund Selling Persists</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DotBio-B Falls 5.04% in Regular Trading, ASCO Rebound Fades as Southbound Fund Selling Persists\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-09 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 9, DotBio-B declined 5.04% in regular trading, trading at HK$171.6/share, with trading volume of HK$37.87 million. The stock continues its downward trend after a brief ASCO-driven rebound on June 5 proved short-lived.</p><p>The company staged a 6% bounce on June 5 supported by consecutive share buybacks and positive ASCO clinical data catalysts, including Phase I data for its B7-H4 ADC DB-1312/BG-C9074 partnered with BeiGene. However, the rebound failed to hold, with the stock falling 5.25% on June 8 as selling pressure overwhelmed buyback efforts. Despite repurchasing a cumulative 262,400 shares since late May totaling approximately HK$53.3 million year-to-date, the company has been unable to stem persistent outflows. Southbound funds have reduced holdings by approximately 2.86 million shares over the past 20 trading days, bringing their stake down to around 29.66% of issued shares.</p><p>The broader Biotechnology sector is under significant pressure today, with Innovent Bio down 4.37%, Akeso down 3.79%, Remegen down 3.49%, BeiGene down 2.33%, and SKB Bio down 1.57%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1143006270","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143006270","pubTimestamp":1780969836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 9, DotBio-B declined 5.04% in regular trading, trading at HK$171.6/share, with trading volume of HK$37.87 million. The stock continues its downward trend after a brief ASCO-driven rebound on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动向提示|DotBio-B常规交易跌5.04%，南向资金抛售持续，ASCO反弹消退","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On June 9, DotBio-B declined 5.04% in regular trading, trading at HK$171.6/share, with trading volume of HK$37.87 million. The stock continues its downward trend after a brief ASCO-driven rebound on June 5 proved short-lived.The company staged a 6% bounce on June 5 supported by consecutive share buybacks and positive ASCO clinical data catalysts, including Phase I data for its B7-H4 ADC DB-1312/BG-C9074 partnered with BeiGene. However, the rebound failed to hold, with the stock falling 5.25% on June 8 as selling pressure overwhelmed buyback efforts. Despite repurchasing a cumulative 262,400 shares since late May totaling approximately HK$53.3 million year-to-date, the company has been unable to stem persistent outflows. Southbound funds have reduced holdings by approximately 2.86 million shares over the past 20 trading days, bringing their stake down to around 29.66% of issued shares.The broader Biotechnology sector is under significant pressure today, with Innovent Bio down 4.37%, Akeso down 3.79%, Remegen down 3.49%, BeiGene down 2.33%, and SKB Bio down 1.57%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143006270","isCrawlerRequest":true}